Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
Over the past 10 years, PARP inhibitors, immunotherapy and antibody drug conjugates have changed the treatment landscape of gynecologic ... are inflammation in the skin, so rashes, inflammation in the ...
Health on MSN4d
Does Adjuvant Therapy Prevent Cancer Recurrence?"Neoadjuvant therapy” refers to supplemental cancer treatment you receive before your primary treatment. Adjuvant therapies, ...
has occurred with anti– PD-1/PD-L1 treatments. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. Withhold or permanently discontinue ...
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic ...
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...
The US Food and Drug Administration (FDA) has approved MSD’s KEYTRUDA regimen as a first-line treatment for adults with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback